• S Tag Peptide: Practical Fusion Tag Workflow

  2026-08-21

  The S Tag Peptide is a 15-amino-acid RNase A-derived tag used in genetically encoded S-peptide fusion tags for recombinant protein detection, antibody-based purification, and protein solubility improvement. This guide covers reconstitution, storage, construct design, and QC while identifying boundaries such as ethanol incompatibility and the lack of standalone RNase activity.

• Tetrahydromagnolol: From CB2 Signaling to Translation

  2026-08-20

  Tetrahydromagnolol offers a receptor-resolved entry point into cannabinoid receptor research, anti-inflammatory research, and analgesic mechanism study. By placing its peripheral CB2 pharmacology alongside new evidence that GPCR signaling can activate ERM-dependent motility in triple-negative breast cancer, this article proposes a disciplined strategy for testing—not assuming—a CB2-to-cytoskeleton connection.

• Annexin V-PE Apoptosis Detection Kit Workflow

  2026-08-20

  Use the Annexin V-PE Apoptosis Detection Kit to capture early phosphatidylserine exposure in intact cells, then connect cell-death measurements with inflammatory phenotypes in models such as LPS-stimulated neonatal monocytes. Its fixation-free, 10-minute staining workflow supports both quantitative flow cytometry and spatial fluorescence microscopy.

• Rapamycin (Sirolimus): A Mechanism-First Guide

  2026-08-19

  Rapamycin, also called Sirolimus, is more than a general mTOR inhibitor: it is a causal perturbation tool for separating pathway activity from cell-death phenotype. This guide explains how to apply it in cancer, immunology, lens-cell, and Leigh syndrome mitochondrial disease assays with stronger controls and interpretation.

• MG-132 Workflows for Proteasome-Linked Apoptosis

  2026-08-19

  MG-132 (Z-LLL-al) enables controlled proteasome blockade for apoptosis assay design, cell cycle arrest studies, and mechanistic protein-turnover experiments. This workflow connects the compound to the WWP2–DDX3X endothelial-injury model while emphasizing dose selection, orthogonal validation, and troubleshooting.

• VipF Acetyltransferase Targets eIF3 to Block Translation

  2026-08-18

  Syriste and colleagues define how the conserved Legionella effector VipF acts as a tandem GNAT acetyltransferase and targets the human eIF3-K subunit. Structural, biochemical, interaction, and translation assays connect lysine acetylation of eIF3-K to suppression of protein synthesis in vitro, providing a mechanistic explanation for a previously uncharacterized core effector family.

• Honokiol Workflows for NF-κB and T-Cell Assays

  2026-08-18

  Honokiol supports controlled studies of NF-κB signaling, oxidative stress, tumor biology, and inflammation without conflating growth arrest with cell death. This workflow connects those established assay uses with a metabolic-flexibility framework inspired by CD8+ T-cell research, while clearly separating evidence from exploratory application.

• 3X (DYKDDDDK) Peptide for Reliable Assays

  2026-08-17

  Learn how 3X (DYKDDDDK) Peptide, SKU A6001, can strengthen upstream protein verification in cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers compatibility, handling, metal-sensitive detection, data interpretation, and practical vendor selection without presenting the peptide as a direct viability reagent.

• Carvedilol Phosphate in Hepatic IRI Research

  2026-08-17

  Carvedilol Phosphate offers a practical way to perturb adrenergic signaling while studying hepatocyte–macrophage crosstalk in ischemia–reperfusion injury. This guide connects the Arrb2–6-ketoLCA findings to solution preparation, hypoxia–reoxygenation workflows, metabolite measurements, and troubleshooting decisions.

• TRPV1 and TRPA1 Drive TSLP in Nasal Epithelium

  2026-08-16

  The reference study identifies nasal epithelial TRPV1 and TRPA1 as functional sensors that connect environmental stimulation with inflammatory mediator production. Its experiments support a calcium-dependent NFAT mechanism for TSLP secretion, while also revealing that IL-25 and IL-33 responses may not be regulated identically.

• GLP-1 (9-36) amide: Assay Workflows

  2026-08-15

  Use GLP-1 (9-36) amide to separate GLP-1 receptor activity from ligand cross-reactivity in cAMP and metabolic assays. This practical guide combines peptide-handling safeguards, FRET-compatible workflows, comparative controls, and troubleshooting for GLP-1 receptor signaling research.

• QRICH1, HMGB1, and HBV-Linked Hepatic Fibrosis

  2026-08-14

  The reference study identifies QRICH1 as an important effector connecting endoplasmic reticulum stress with HMGB1 transcription, translocation, and secretion during chronic HBV-associated liver injury. Its combination of a recombinant cccDNA mouse model, human fibrosis specimens, histology, serum assays, and molecular analyses supports a mechanistic link between QRICH1, SIRT6-dependent HMGB1 acetylation, and hepatic fibrosis progression.

• MK0787 Antibacterial Spectrum in Clinical Isolates

  2026-08-14

  This 1982 comparative study evaluated N-formimidoyl thienamycin (MK0787) across 470 clinical isolates and positioned it against several recently developed β-lactam antibiotics. Its main contribution was to connect broad in vitro activity with bactericidal behavior and apparent independence from β-lactamase production, while also revealing species-specific differences relative to cefotaxime, moxalactam, and cefoperazone.

• RIPA Lysis Buffer (Strong) for BBB Signaling

  2026-08-13

  RIPA Lysis Buffer (Strong) supports rigorous protein extraction for BBB and neuroinflammation studies. This guide explains how to align detergent strength, inhibitor strategy, cell-type resolution, and assay choice with mechanistic findings from Ginsenoside Rg2 research.

• Integrated Genomics and Immune Vulnerabilities in Mesothelio

  2026-08-13

  This 2021 Scientific Reports study combined copy-number profiling, exome and targeted sequencing, whole-genome sequencing, transcriptomics, and primary mesothelioma cell testing to identify clinically relevant vulnerabilities. Its main contribution is a molecular framework linking SUFU, interferon, CDKN2A, RB1, and Hippo pathway alterations with immune dysregulation, survival, and selective ex vivo drug responses.

15783 records 1/1053 page Next 12345 下5页 Last page